Finance entity

Sun Pharmaceutical Industries

Company

markets is the sole category represented across all 1 tracked stories. Sun Pharmaceutical Industries is most often covered alongside Cipla, which appears in 1 of these 1 story. The 8 average consequence score is above the beat benchmark of 6.3 in the same window.

Last mentioned: Mar 25, 2026

Entity pulse

Recent coverage · Sun Pharmaceutical Industries

1 story
8 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Sun Pharmaceutical Industries

markets is the sole category represented across all 1 tracked stories. Sun Pharmaceutical Industries is most often covered alongside Cipla, which appears in 1 of these 1 story. The 8 average consequence score is above the beat benchmark of 6.3 in the same window. Source depth averages 3 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Finance story that mention Sun Pharmaceutical Industries, all published on March 25, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 84 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Sun Pharmaceutical Industries. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Sun Pharmaceutical Industries 1

Markets Bullish

India Disrupts GLP-1 Market with Low-Cost Weight-Loss Generics

India's pharmaceutical sector has launched a massive rollout of affordable versions of popular weight-loss medications, targeting the global dominance of high-priced GLP-1 agonists. This move threatens the premium pricing models of Western pharmaceutical giants while significantly expanding patient access in price-sensitive emerging markets.

3 sources

Sun Pharmaceutical Industries is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.